{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:10:20Z","timestamp":1784016620320,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Onderzoeksfonds Hematon"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>In anti-myelin-associated glycoprotein IgM paraprotein-related peripheral neuropathy (anti-MAG PN), there is a lack of reliable biomarkers to select patients eligible for therapy and for evaluating treatment effects, both in routine practice and in clinical trials. Neurofilament light chain (NfL) and contactin-1 (CNTN1) can serve as markers of axonal and paranodal damage. Complement activation is involved in the pathogenesis in anti-MAG PN. We, therefore, hypothesized that serum NfL, CNTN1, C3b\/c and C4b\/c may function as biomarkers of disease activity in anti-MAG PN.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective cohort study, we included 24\u00a0treatment-na\u00efve patients with anti-MAG PN (mean age 69\u00a0years, 57% male) that had IgM paraproteinemia, a high IgM MAG-antibody, and clinical diagnosis of anti-MAG PN by a neurologist specialized in peripheral nerve disorders. We measured serum NfL, CNTN1, C3b\/c and C4b\/c, reference values were based on healthy controls. As controls, 10 treatment-na\u00efve patients with IgM Monoclonal gammopathy of undetermined significance (MGUS) or Waldenstr\u00f6m\u2019s Macroglobulinemia (mean age 69\u00a0years, 60% male) without signs of neuropathy were included (non-PN).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>NfL, CNTN1 levels in serum were mostly normal in anti-MAG PN patients and comparable to non-PN patients. C3b\/c and C4b\/c levels were normal in anti-MAG PN patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results do not support serum NfL, CNTN1, and C3b\/c and C4b\/c as potential biomarkers in anti-MAG PN, although we cannot exclude that subgroups or subtle abnormalities could be found in a much larger cohort with longitudinal follow-up.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00415-022-10993-4","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T14:08:34Z","timestamp":1644847714000},"page":"3700-3705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy"],"prefix":"10.1007","volume":"269","author":[{"given":"Karima","family":"Amaador","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Wieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen J. A.","family":"Koel-Simmelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Jongerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"de Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolette C.","family":"Notermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3229-9556","authenticated-orcid":false,"given":"Josephine M. I.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"issue":"5","key":"10993_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/jnnp-2017-316715","volume":"89","author":"J Svahn","year":"2018","unstructured":"Svahn J, Petiot P, Antoine JC, Vial C, Delmont E, Viala K et al (2018) Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. J Neurol Neurosurg Psychiatry 89(5):499\u2013505","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 5","key":"10993_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/brain\/117.5.949","volume":"117","author":"IS Smith","year":"1994","unstructured":"Smith IS (1994) The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study. Brain 117(Pt 5):949\u2013957","journal-title":"Brain"},{"key":"10993_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/WCO.0000000000000975","volume":"34","author":"N Latov","year":"2021","unstructured":"Latov N (2021) Antibody testing in neuropathy associated with anti-Myelin-Associated Glycoprotein antibodies: where we are after 40 years. Curr Opin Neurol 34:625\u2013630","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"10993_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/jnnp-2017-316689","volume":"89","author":"JM Vos","year":"2018","unstructured":"Vos JM, Notermans NC, D\u2019Sa S, Lunn MP, van der Pol WL, Kraan W et al (2018) High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. J Neurol Neurosurg Psychiatry 89(9):1007\u20131009","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u20132","key":"10993_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jns.2007.09.020","volume":"266","author":"E Nobile-Orazio","year":"2008","unstructured":"Nobile-Orazio E, Gallia F, Terenghi F, Allaria S, Giannotta C, Carpo M (2008) How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci 266(1\u20132):156\u2013163","journal-title":"J Neurol Sci"},{"issue":"5","key":"10993_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/00207454.2016.1191013","volume":"127","author":"G Galassi","year":"2017","unstructured":"Galassi G, Tondelli M, Ariatti A, Benuzzi F, Nichelli P, Valzania F (2017) Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein (MAG) antibodies. Int J Neurosci 127(5):439\u2013447","journal-title":"Int J Neurosci"},{"key":"10993_CR7","first-page":"1","volume":"2021","author":"L Wieske","year":"2021","unstructured":"Wieske L, Smyth D, Lunn MP, Eftimov F, Teunissen CE (2021) Fluid biomarkers for monitoring structural changes in polyneuropathies: their use in clinical practice and trials. Neurotherapeutics 2021:1\u201317","journal-title":"Neurotherapeutics"},{"issue":"11","key":"10993_CR8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.nmd.2017.08.001","volume":"27","author":"MHJ Pruppers","year":"2017","unstructured":"Pruppers MHJ, Merkies ISJ, Lunn MPT, Notermans NC (2017) 230th ENMC International Workshop: Improving future assessment and research in IgM anti-MAG peripheral neuropathy: a consensus collaborative effort, Naarden, The Netherlands, 24\u201326 February 2017. Neuromuscul Disord 27(11):1065\u20131072","journal-title":"Neuromuscul Disord"},{"issue":"15","key":"10993_CR9","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R et al (2015) Ibrutinib in previously treated waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med 372(15):1430\u20131440","journal-title":"N Engl J Med"},{"key":"10993_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.21.00105","volume":"40","author":"MJ Kersten","year":"2021","unstructured":"Kersten MJ, Amaador K, Minnema MC, Vos JMI, Nasserinejad K, Kap M et al (2021) Combining ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory waldenstr\u00f6m\u2019s macroglobulinemia: final analysis of the phase I\/II HOVON124\/ECWM-R2 study. J Clin Oncol 40:40\u201351","journal-title":"J Clin Oncol"},{"key":"10993_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/brainsci11020132","volume":"11","author":"C Briani","year":"2021","unstructured":"Briani C, Ferrari S, Campagnolo M, Tagliapietra M, Castellani F, Salvalaggio A et al (2021) Mechanisms of nerve damage in neuropathies associated with hematological diseases: lesson from nerve biopsies. Brain Sci 11:2","journal-title":"Brain Sci"},{"issue":"2","key":"10993_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jns.12319","volume":"24","author":"GGA van Lieverloo","year":"2019","unstructured":"van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, Michalak Z et al (2019) Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 24(2):187\u2013194","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"10993_CR13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/annrheumdis-2017-212045","volume":"77","author":"A Bischof","year":"2018","unstructured":"Bischof A, Manigold T, Barro C, Heijnen I, Berger CT, Derfuss T et al (2018) Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy. Ann Rheum Dis 77(7):1093\u20131094","journal-title":"Ann Rheum Dis"},{"issue":"15 Supplement","key":"10993_CR14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1212\/WNL.94.15_supplement.771","volume":"94","author":"P Nioi","year":"2020","unstructured":"Nioi P, Ticau S, Sridharan G, Tsour S, Cantley W, Chan A et al (2020) Neurofilament light chain (NfL) as a potential biomarker in hereditary transthyretin-mediated (hATTR) amyloidosis (771). Neurology 94(15 Supplement):771","journal-title":"Neurology"},{"issue":"10","key":"10993_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577\u2013589","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10993_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/jns.12279","volume":"23","author":"S Mariotto","year":"2018","unstructured":"Mariotto S, Farinazzo A, Magliozzi R, Alberti D, Monaco S, Ferrari S (2018) Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst 23(3):174\u2013177","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10993_CR17","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1212\/NXI.0000000000001040","volume":"8","author":"L Wieske","year":"2021","unstructured":"Wieske L, Mart\u00edn-Aguilar L, Fehmi J, Lleix\u00e0 C, Koel-Simmelink MJA, Chatterjee M et al (2021) Serum contactin-1 in CIDP. Neurol Neuroimmunol Neuroinflamm 8(5):1040","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10993_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/NEN.0b013e3181fa44af","volume":"69","author":"Y Kawagashira","year":"2010","unstructured":"Kawagashira Y, Koike H, Tomita M, Morozumi S, Iijima M, Nakamura T et al (2010) Morphological progression of myelin abnormalities in IgM-monoclonal gammopathy of undetermined significance anti-myelin-associated glycoprotein neuropathy. J Neuropathol Exp Neurol 69(11):1143\u20131157","journal-title":"J Neuropathol Exp Neurol"},{"issue":"7","key":"10993_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1158\/2326-6066.CIR-20-0922","volume":"9","author":"TR Emmons","year":"2021","unstructured":"Emmons TR, Giridharan T, Singel KL, Khan ANH, Ricciuti J, Howard K et al (2021) Mechanisms driving neutrophil-induced T-cell immunoparalysis in ovarian cancer. Cancer Immunol Res 9(7):790\u2013810","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10993_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12974-020-01737-0","volume":"17","author":"P Altmann","year":"2020","unstructured":"Altmann P, De Simoni D, Kaider A, Ludwig B, Rath J, Leutmezer F et al (2020) Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barr\u00e9 syndrome. J Neuroinflamm 17(1):86","journal-title":"J Neuroinflamm"},{"issue":"1\u20132","key":"10993_CR21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/S0165-5728(99)00252-0","volume":"106","author":"MA De Letter","year":"2000","unstructured":"De Letter MA, van Doorn PA, Savelkoul HF, Laman JD, Schmitz PI, de Coul AA et al (2000) Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol 106(1\u20132):206\u2013213","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10993_CR22","doi-asserted-by":"publisher","first-page":"e1109","DOI":"10.1212\/NXI.0000000000001109","volume":"9","author":"P H\u00e4nggi","year":"2022","unstructured":"H\u00e4nggi P, Aliu B, Martin K, Herrendorff R, Steck AJ (2022) Decrease in serum anti-MAG autoantibodies is associated with therapy response in patients with anti-MAG neuropathy. Neurol Neuroimmunol Neuroinflamm 9(1):e1109","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-10993-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-10993-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-10993-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T14:22:13Z","timestamp":1726669333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-10993-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10993"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-10993-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"3 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no significant competing financial, professional, or personal interests that might have influenced the performance or presentation of the work described in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}